Objective: To evaluate by survey the comfort upon instillation of timolol hemihydrate compared to timolol maleate with potassium sorbate.
INTRODUCTION
Timolol hemihydrate (Betimol ® , Vistakon Pharmaceuticals, LLC, Jacksonville, FL) was introduced in the 1990s as a low cost alternative to traditional timolol maleate therapy. At that time it was shown that it could be used, like timolol maleate, once daily with equal 24-hour efficacy as monotherapy or added to latanoprost. [1] [2] [3] Several years ago a new timolol maleate preparation became available (Istalol ® , ISTA Pharmaceuticals, Inc., Irvine, CA) as an alternative once daily prescribed betablocker. This preparation contains potassium sorbate which enhances ocular bioavailability, allowing for once daily dosing. 4 However, timolol maleate with potassium sorbate has been shown to sting upon instillation in approximately 42% of patients. 5 This study was conducted to evaluate (by survey) the comfort upon instillation of timolol hemihydrate compared to timolol maleate with potassium sorbate.
MATERIALS AND METHODS
This was a prospective, multicenter, observational (non interventional) study that was performed at seven clinical sites in the United States. The trial was registered with Clinicaltrials.gov, NCT00823043. This study was approved by the Institutional Review Board-Schulman Associates Institutional Review Board, Inc. (SAIRB), 4290 GlendaleMilford Road, Cincinnati, Ohio 45242-and adhered to the tenets of the Declaration of Helsinki. We included patients of open-angle glaucoma or ocular hypertension who were >21 years old and were currently prescribed timolol hemihydrate (once or twice daily) or timolol maleate with potassium sorbate once daily as monotherapy or as a part of two-drug therapy. With timolol hemihydrate if one eye was treated QD and the other BID, the QD eye was chosen as the study eye. Similarly, if dosed with two medicines in one eye and one medicine in the other, the lower dosed eye was chosen for the study.
Appropriate consecutive patients who agreed to complete the survey were entered into the trial. After signing informed consent, subjects provided demographic information, medication and ophthalmic history, and then completed a 10-question survey about the comfort and influence on activities of daily living of their current glaucoma medication.
Subjects who met any of the following criteria were not qualified to be enrolled in the trial:
• Inability to understand the trial procedures and thus inability to give informed consent.
• Inability to understand, read or write English.
• Best corrected visual acuity of 20/200 or worse in each eye.
• Current moderate to severe infectious or inflammatory condition of the eye or eyelids including: Blepharitis, conjunctivitis, keratitis or uveitis.
• Current moderate to severe dry eye syndrome.
• Current chronic use of ocular corticosteroids.
• Ocular surgery or intraocular laser surgery to either eye in the prior 3 months. • Treated with three or more glaucoma medicines in both eyes. All data collected in the study were from the survey and no patient identifying information was kept. No randomization of treatment assignments was conducted but in general, investigational sites balanced the surveys collected between both groups of treated patients. Investigators were instructed regarding the protocol and related materials during a Site Initiation Teleconference conducted by the Clinical Research Associate (CRA) who had been trained by the CRO. Investigational sites were instructed to review each subject's survey to ensure all questions had been answered before collecting from the subject. The same CRA conducted a study close-out teleconference.
No safety and efficacy variables were measured in the study. The endpoints evaluated were each subject's response to survey questions about their current timolol treatment.
Patient survey shows the survey questionnaire. A 5 point scoring (0 to 4) was done for each of the questions. All questions were analyzed between timolol hemihydrate vs timolol maleate with potassium sorbate with a Student's t-test except question 9 which was evaluated with a Chisquare test. 6 All analyses were two-tailed, with a p-value of 0.05 used to declare statistical significance. 
Patient survey

RESULTS
The study included 103 patients from seven centers. The demographic and baseline data is elucidated in 
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for questions 1 (burning/stinging on instillation, p < 0.001) and 4 (tearing on instillation, p = 0.024). However, there were no differences between treatment groups for any other question (p > 0.05). Also, there was little effect on activities of daily living. Question 9 noted that nine patients (14%) treated with timolol hemihydrate and 6 (15%) with timolol maleate with potassium sorbate were limited to at least one daily activity of living that they ascribed to the beta-blocker therapy (p = 0.41).
The same statistical results as with the complete patient population also held with subanalyses of timolol hemihydrate once daily or twice daily vs timolol maleate with potassium sorbate, or mono-or adjunctive treatment with timolol hemihydrate vs timolol maleate with potassium sorbate. In contrast, no differences were observed for any question between timolol hemihydrate once daily vs twice daily treatment (p > 0.05) ( Tables 3 to 7) .
DISCUSSION
Timolol maleate formulation combined with sorbate has the advantage of better penetration due to enhanced lipophilicity, but maleate is a salt of an organic acid that has several types of cellular effects. It reduces glutathione, a free radical scavenger, in both epithelial and endothelial cells and in corneal endothelial cells specifically. 7 Timolol hemihydrate eliminates the maleate buffer and simplifies the purification step for the R-enantiomer. Betimol ® is an isotonic, microbiologically preserved aqueous solution which has monosodium and disodium phosphate dihydrate to adjust its pH (6.5-7.5) and an osmolality of 260 to 320 mOsmol/kg. Timolol maleate too has a pH of 6.5 to 7.5 and an osmolality of 275 to 330 mOsmol/kg. Despite The reason for the differences between these medications in comfort were not clear by the results of this survey. Past research has also not been able to elucidate if the irritation from timolol maleate results from the active ingredient or the maleate. The lack of effect on activities of daily living may have been related to the resolution of any postinstillation stinging/burning or tearing before these daily activities needed to be performed.
Sonty S et al compared the symptoms and tolerability of once daily timolol hemihydrate 0.5%, timolol in sorbate 0.5%, and timolol gel-forming solution 0.5% in patients with glaucoma and/or ocular hypertension and found that the short-term (3-day) administration of timolol in sorbate was associated with more stinging or burning compared with timolol hemihydrate and timolol gel-forming solution. 8 Our survey did not evaluate symptoms or signs after instillation or adherence in a randomized prospective clinical trial. Further research is needed to analyze anterior segment safety between these two beta-blockers as well as to describe the mechanism of stinging associated with timolol maleate with potassium sorbate.
SUMMARY
This survey demonstrates that topical timolol hemihydrate is associated with less stinging/burning and tearing than timolol maleate with potassium sorbate.
